What should you know about lobular intraepithelial neoplasia?

This finding is commonly made from breast tissue obtained during a biopsy. The cells remain within the lobular structures, so the term does not by itself mean that an invasive tumour is present. The report may use terms such as classic LCIS, atypical lobular hyperplasia, or another subtype, and those distinctions can change the next step.

The radiologist and pathologist compare the tissue result with the scan. If the biopsy does not explain the imaging finding, the team may recommend further tissue assessment. Your personal and family history, breast density, age, and previous procedures can also shape the monitoring plan.

Your clinician may recommend structured breast surveillance, additional imaging, or a procedure to obtain more tissue. Risk-reducing endocrine therapy is another option for some people; the decision weighs potential benefit against effects on periods, menopause symptoms, bones, blood vessels, and daily life.

Keep the pathology wording and imaging reports together for future visits. Tell the team about pregnancy plans, hormone medicines, previous clots, bone conditions, and close relatives with breast or ovarian cancer. Follow-up works best when you know which service arranges each examination and how results will be communicated.

Report a new lump, persistent thickening, nipple inversion, bloody discharge, skin puckering, or a noticeable change in breast size or shape. A symptom does not prove that the lobular finding has progressed, but a new change should be examined. After a biopsy, contact the clinic for increasing redness, drainage, fever, or bleeding that does not settle.

Ask which form of lobular intraepithelial neoplasia was identified, whether the biopsy matches the imaging, and whether a surgical excision is needed. Ask how often each breast should be checked, whether endocrine risk reduction fits you, and what symptoms should prompt an earlier appointment.